This interview features Steve Garbon, Director of Finance at the Braff Group, where he delves into M&A transactions and valuations.
Amazon continues to stay mum on its healthcare ambitions but if you put the pieces together, it’s clear there’s some sort of play in the works. This past year, rumors swirled around the clandestine 1492 lab, focused, among other things, on electronic medical records and telemedicine. Then there was the string of filings with state […]
The marijuana industry is worth as much as $35 billion per year. As legal restrictions are eased, will this mean M&A activity?
As recently noted in a Wall Street Journal article, some private equity (PE) firms have begun partnering with pharmaceutical companies, though in a manner far from traditional.
As far as daytime dramas go, the the White House Administration’s ongoing challenges in passing its healthcare bill continue to dominate the news and make for “must-see” TV. After years of declaring they’d repeal the Affordable Care Act (AKA Obamacare) at the first chance possible, Republicans finally gain control of elected government and find they […]
Dealmaking activity in the pharmaceutical and biotechnology industries remained strong in 2016, in contrast to M&A levels in many other sectors.
Tax inversions are still legal, but are they still on the way out? Here's what the failed Pfizer-Allergan deal showed us.
Monoclonal antibodies represent one of the most successful therapeutic drug classes, attracting billions of investment dollars for the biotech industry.
Touchpoint by Firmex highlights the human dimension of corporate transactions, dealmaking, and the relationships behind them.
Get TOUCHPOINT stories delivered straight to your inbox.
